Literature DB >> 15855754

Treatment of small intestine bacterial overgrowth and related symptoms by rifaximin.

Michele Di Stefano1, Gino Roberto Corazza.   

Abstract

The treatment of small intestine bacterial overgrowth should address different aims: the removal of the predisposing condition, guarantee of adequate nutritional support to reintegrate both caloric and vitamin requirements and, obviously, suppression of the contaminating bacterial flora, which represents the major goal. The polymicrobic nature of contaminating flora suggests the administration of wide-spectrum antibiotics, but until now there has been no conclusive information on the most effective therapeutic approach. In this paper, the efficacy of the different therapeutic approaches used is reviewed. Copyright (c) 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15855754     DOI: 10.1159/000081996

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  5 in total

1.  Small intestinal bacterial overgrowth in irritable bowel syndrome: are there any predictors?

Authors:  Savio C Reddymasu; Sandra Sostarich; Richard W McCallum
Journal:  BMC Gastroenterol       Date:  2010-02-22       Impact factor: 3.067

Review 2.  Irritable bowel syndrome and small intestinal bacterial overgrowth: meaningful association or unnecessary hype.

Authors:  Uday C Ghoshal; Deepakshi Srivastava
Journal:  World J Gastroenterol       Date:  2014-03-14       Impact factor: 5.742

3.  Small intestinal bacterial overgrowth and lactose intolerance contribute to irritable bowel syndrome symptomatology in Pakistan.

Authors:  Javed Yakoob; Zaigham Abbas; Rustam Khan; Saeed Hamid; Safia Awan; Wasim Jafri
Journal:  Saudi J Gastroenterol       Date:  2011 Nov-Dec       Impact factor: 2.485

4.  Determination of rifaximin treatment period according to lactulose breath test values in nonconstipated irritable bowel syndrome subjects.

Authors:  Suhyun Bae; Kwang Jae Lee; Young-Sang Kim; Kyu-Nam Kim
Journal:  J Korean Med Sci       Date:  2015-05-13       Impact factor: 2.153

5.  Irritable Bowel Syndrome May Be Associated with Elevated Alanine Aminotransferase and Metabolic Syndrome.

Authors:  Seung Hwa Lee; Kyu Nam Kim; Kwang Min Kim; Nam Seok Joo
Journal:  Yonsei Med J       Date:  2016-01       Impact factor: 2.759

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.